Regional rainfall threshold maps drawn through multivariate geostatistical techniques for shallow landslide hazard zonation.

The Empirical Rainfall Thresholds (ERTs) for shallow landslide initiation are commonly devised worldwide mostly to be implemented within landslide early warning systems. Nonetheless, since the pioneering works on ERTs in the 1980s, only meteorological variables - that are cumulated E or intensity I and duration D values of rainfalls that are likely to trigger landslides - have been used to predict landslide occurrence, even though they are characterized by a large uncertainty. Over time, many efforts have been devoted to constrain ERT to geo-morphological characters of the landslide locations but, since nowadays, they did not get to a sound new method to derive ERT and strengthen its ability to forecast future rainfall-induced landslide.

Modeling 3D soil lithotypes variability through geostatistical data fusion of CPT parameters.

The Cone Penetration Test (CPT) measures enable to recognize vertical lithological sequence at each investigated point. From the tip resistance q and sleeve resistance f profiles, the Soil Behavior Type index I has been calculated, in order to identify the lithotypes alongside depth. The present study focuses on the combination of different variables to provide a lithological and mechanical subsoil characterization.

Predictive factors for 6 12 cycles of Folfiri-Bevacizumab in metastatic colorectal cancer.

Early switching to de-intensified maintenance regimen is still a matter of debate in metastatic colorectal cancer (mCRC). The MARTHA trial, a S.I.

Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF Regimen) in patients with metastatic colorectal cancer: the southern Italy cooperative oncology group experience.

Background: We have extensively assessed a biweekly regimen of irinotecan plus folinic acid and fluorouracil bolus (IRIFAFU) in metastatic colorectal cancer (MCRC). Here, we report on the safety and activity of BIFF (bevacizumab plus IRIFAFU) regimen in 94 mCRC patients.

Patients And Methods: Bevacizumab 5 mg/kg (1 hour), and irinotecan 180 mg/m(2) (1 hour) were given intravenously on day 1, 6S-folinic acid 250 mg/m(2) (2 hours), and fluorouracil 850 mg/m(2) (bolus) were given intravenously on day 2 every 2 weeks for a median of 9 cycles per patient (range, 1-12), and maintenance bevacizumab alone was delivered in 16 cases.

Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer: a randomized phase II SICOG trial.

Purpose: To estimate the safety, activity, and impact on quality of life of a combination of gemcitabine and pemetrexed in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) in the context of a randomized two-stage phase II study.

Patients And Methods: Patients in stage IIIB or IV NSCLC were randomly allocated to receive either gemcitabine 1250 mg/m(2) on day 1, and pemetrexed (Alimta) 500 mg/m(2) followed by gemcitabine 1250 mg/m(2) on day 8 of a 3-weekly cycle (GA arm), or paclitaxel 120 mg/m(2) followed by gemcitabine 1000 mg/m(2), both given on days 1 and 8 of a 3-weekly cycle (PG arm).

Results: 105 (GA arm, 51; PG arm, 54) eligible patients (stage IV, 32 and 30, respectively) were enrolled into this study; thereafter, accrual was stopped due to first-stage analysis.